Navigation Links
Entinostat Demonstrates Activity in Hodgkin's Lymphoma
Date:12/11/2011

WALTHAM, Mass., Dec. 11, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma (HL).  This data is being presented today, December 11, from 6:00 to 8:00 PM PT at the American Society of Hematology Annual Meeting and Exposition in San Diego.  

"Showing activity in this hard-to-treat patient population, demonstrates potential for entinostat to treat Hodgkin's lymphoma," said Anas Younes, MD, professor, department of lymphoma/myeloma, division of cancer medicine, The University of Texas MD Anderson Cancer Center. "These results are consistent with what has been seen with other HDAC inhibitors with a lower rate of toxicity warranting further study of entinostat particularly in combination strategies and at an earlier stage of disease."

Highlights of the data include:

  • Antitumor activity observed in HL patients progressing after SCT with bulky disease in about a third of patients within two cycles of therapy
  • Progression-free survival (PFS) showed durable responses in bulky disease patients
  • Overall survival (OS) was an exploratory endpoint with data that is still maturing
  • Entinostat was well tolerated and the safety profile is consistent with previous studies allowing for future combination treatments.

"We are pleased to see that the results of ENGAGE 501 provide evidence of single-agent activity for entinostat in Hodgkin's lymphoma," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "Given this data combined with the recently reported '/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
2. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
3. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
4. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
5. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
6. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
7. RVX-208 Data Demonstrates Increase in Functional HDL Particles
8. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
9. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
10. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
11. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NJ (PRWEB) May 21, 2015 Patent ... a method for diagnostic or therapeutic imaging within a ... apparatus uses an endoscope having a low cost, single-use ... USPTO filing date was October 18, 2013 and the ... The technology enables the physician to customize the lighting ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
(Date:5/20/2015)... global genotyping market is expected to grow at a ... to 2020 to reach $17.0billion in 2020. Genotyping tests ... process and to provide personalized therapy, factors that are ... key manufacturers to offer advanced and innovative products for ... market data tables & 37 figures spread through 200 ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... DARA BioSciences(TM),(Nasdaq: DARA ) announced today the appointment ... Mr. Cochrane was appointed to fill a Board,vacancy and ... appointment was effective February 21, 2008., In making ... are pleased that Haywood has joined us as a ...
... PITTSBURGH, Feb. 27 Mylan Inc. (NYSE: ... Holdings, Ltd., a wholly,owned subsidiary of Forest Laboratories, ... 2006 agreement to commercialize, develop and distribute the,novel ... in,the United States for the treatment of hypertension. ...
... ZARS Pharma, Inc. announced,today that Rapydan(R) (70 ... received marketing authorization in Sweden, the United ... Republic, Greece, Ireland,Norway and Portugal following the ... Pharma has licensed the European sales and,marketing ...
Cached Biology Technology:DARA BioSciences, Inc. Announces Appointment of New Director to Board 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 3ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 2ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 3
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... University has completed the first comprehensive map of the ... of higher organisms operate, according to a report this ... is a breakthrough in understanding mechanisms of how proteins ... master regulator molecules called protein kinases. Although protein kinases ...
... volcanic rock in Mexico are either extremely old - more ... presence in the Western Hemisphere - or not footprints at ... Nature. , The study was conducted by geologists at the ... part of an investigative team of geologists and anthropologists from ...
... strand of molecules plays a role in how our arms ... light on perplexing bits of material once dismissed as genetic ... University. , The research, available today in the online edition ... called microRNAs act as protective mechanisms in healthy development not ...
Cached Biology News:Yale scientists decipher 'wiring pattern' of cell signaling networks 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 3Alleged 40,000-year-old human footprints in Mexico much, much older than thought 4MicroRNA may have fail-safe role in limb development 2